News Headlines

  1. IDEAYA Biosciences Announces Clinical Collaboration With Genentech In MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer 8/19/2026

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS G12D inhibitor, in patients with pancreatic ductal adenocarcinoma (PDAC) harboring both an MTAP-deletion and a KRAS G12D mutation.

  2. Amplitude Therapeutics And Lilly Enter Strategic Collaboration To Develop Trans-Amplifying RNA Vaccines For Infectious Diseases 8/19/2026

    Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, today announced a strategic research collaboration and licensing agreement with Eli Lilly and Company ("Lilly") to discover and develop taRNA vaccine candidates for infectious diseases.

  3. Piramal Pharma Limited Completes Acquisition Of Controlling Stake In Yapan Bio Private Limited 8/18/2026

    Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore INR, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL.

  4. Dunbar Pharma Brings First Plant-Derived Dronabinol API To UK Market Through IPS Pharma 8/18/2026

    Dunbar Pharmaceuticals (“Dunbar Pharma” or “the Company”), Ireland's first EU GMP-certified manufacturer of plant-derived cannabinoid active pharmaceutical ingredients (APIs), today announced that its plant-derived dronabinol API, WaterClear THC™, is now available across the United Kingdom.

  5. Chugai And GSK Sign Exclusive License Agreement For Anti-Dengue Virus Antibody AID351 8/18/2026

    Chugai Pharmaceutical Co., Ltd. announced that it has signed an exclusive license agreement with GSK for the anti-dengue virus antibody “AID351” on August 17, 2026. This agreement follows the collaboration agreement for AID351 signed between the two companies on January 30, 2025.

  6. Asimov Announces Cell Line Development Partnership With Kaigene To Advance Multispecific Antibody For Autoimmune Disease 8/18/2026

    Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a cell line development partnership with Kaigene, a biotechnology company pioneering next-generation antibody therapeutics for pathogenic antibody-mediated autoimmune diseases.

  7. Genprex Selects Leading Clinical And Commercial Contract Development And Manufacturing Organization For Manufacturing Scale Up Of Diabetes Gene Therapy 8/18/2026

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy program.

  8. VectorBuilder And Lir Therapeutics Partner To Advance AAV Capsids Designed For Clinical Success 8/18/2026

    VectorBuilder, a global leader in gene delivery technologies, and Lir Therapeutics, a company pushing the boundaries of vector engineering with AI, today announced a strategic collaboration to develop adeno-associated virus (AAV) capsids designed not only for strong biological performance, but also for the manufacturability and scalability required to bring gene therapies into the clinic.

  9. Andelyn Biosciences to Implement Curator® Platform To Develop And Manufacture Gene Therapy AAV9-GM2 For Queen's University To Treat GM2 Gangliosidoses 8/18/2026

    Andelyn Biosciences, Inc., a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen's University to develop and manufacture AAV9-GM2, a gene therapy candidate for the treatment of GM2 gangliosidoses, such as Tay-Sachs and Sandhoff diseases.

  10. Vector Science And Therapeutics Corp. Signs Amended, 10-Year Manufacturing And Testing Agreement With LyoGenesis Holdings 8/17/2026

    Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") announced today that its subsidiary, Vector Science and Therapeutics Operating Corp. ("VST"), has entered into an Amended and Restated Exclusive License and Manufacturing Agreement (the "Agreement"), effective August 13, 2026, with LyoGenesis Holdings LLC ("LyoGenesis"), amending and restating the parties' prior agreement dated July 6, 2026.